Study shows nu.q® lung cancer test differentiated malignant and benign nodules found by low dose ct screening

Henderson, nev. , dec. 10, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its nu.q® cancer test differentiated between malignant and benign pulmonary nodules, found by low dose ct (ldct) scan, in patients suspected of lung cancer.
VNRX Ratings Summary
VNRX Quant Ranking